Catalent (NYSE:CTLT) Now Covered by Analysts at StockNews.com

Equities research analysts at StockNews.com began coverage on shares of Catalent (NYSE:CTLT) in a report issued on Sunday. The brokerage set a “hold” rating on the stock.

Other equities analysts also recently issued reports about the company. Baird R W downgraded Catalent from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, September 24th. Robert W. Baird reaffirmed a “neutral” rating and issued a $63.50 price objective on shares of Catalent in a research note on Tuesday, September 24th. Eight investment analysts have rated the stock with a hold rating, According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $63.40.

Catalent Stock Performance

NYSE CTLT opened at $63.48 on Friday. Catalent has a 1-year low of $41.15 and a 1-year high of $63.50. The company has a market capitalization of $11.52 billion, a P/E ratio of -28.09, a PEG ratio of 2.70 and a beta of 1.15. The business has a 50 day moving average price of $61.74 and a 200 day moving average price of $60.11. The company has a debt-to-equity ratio of 1.38, a current ratio of 2.51 and a quick ratio of 1.96.

Catalent (NYSE:CTLT) last released its quarterly earnings data on Tuesday, November 5th. The company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of $0.05 by ($0.18). Catalent had a negative net margin of 9.28% and a negative return on equity of 0.66%. The firm had revenue of $1.02 billion during the quarter, compared to analysts’ expectations of $1.06 billion. During the same period in the previous year, the business earned ($0.10) earnings per share. The business’s revenue for the quarter was up 4.2% on a year-over-year basis. Sell-side analysts expect that Catalent will post 0.78 EPS for the current fiscal year.

Insider Buying and Selling at Catalent

In other news, Director Michelle R. Ryan sold 2,800 shares of the firm’s stock in a transaction on Monday, November 11th. The stock was sold at an average price of $59.70, for a total transaction of $167,160.00. Following the sale, the director now owns 10,835 shares in the company, valued at $646,849.50. This trade represents a 20.54 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 0.31% of the stock is owned by insiders.

Institutional Investors Weigh In On Catalent

Several hedge funds have recently made changes to their positions in the business. JPMorgan Chase & Co. boosted its holdings in shares of Catalent by 15.1% during the third quarter. JPMorgan Chase & Co. now owns 1,520,308 shares of the company’s stock worth $92,085,000 after purchasing an additional 199,427 shares during the last quarter. Oddo BHF Asset Management Sas acquired a new position in Catalent in the third quarter valued at $8,480,000. Tidal Investments LLC acquired a new position in Catalent in the third quarter valued at $214,000. Neo Ivy Capital Management acquired a new position in Catalent in the third quarter valued at $1,078,000. Finally, Nomura Asset Management Co. Ltd. boosted its holdings in Catalent by 1.4% in the third quarter. Nomura Asset Management Co. Ltd. now owns 53,011 shares of the company’s stock valued at $3,211,000 after acquiring an additional 750 shares during the last quarter.

Catalent Company Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.